Drug Profile
Research programme: small molecule cancer therapeutics - FORMA Therapeutics/Nanosyn
Alternative Names: Epigenetics cancer therapeutics; Protein homeostatis cancer therapeuticsLatest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator FORMA Therapeutics; Nanosyn
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 28 Aug 2018 No recent reports of development identified for research development in Cancer in USA
- 29 Jul 2014 Early research in Cancer in USA (unspecified route)